Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2001 1
2002 1
2003 2
2004 1
2005 2
2006 1
2008 2
2009 5
2010 3
2011 5
2012 7
2013 8
2014 6
2015 6
2016 6
2017 3
2018 11
2019 29
2020 30
2021 37
2022 20
2023 17
2024 39
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Results by year

Filters applied: . Clear all
Page 1
Pathology and Classification of SCLC.
Raso MG, Bota-Rabassedas N, Wistuba II. Raso MG, et al. Cancers (Basel). 2021 Feb 16;13(4):820. doi: 10.3390/cancers13040820. Cancers (Basel). 2021. PMID: 33669241 Free PMC article. Review.
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
Kim J, Lee HM, Cai F, Ko B, Yang C, Lieu EL, Muhammad N, Rhyne S, Li K, Haloul M, Gu W, Faubert B, Kaushik AK, Cai L, Kasiri S, Marriam U, Nham K, Girard L, Wang H, Sun X, Kim J, Minna JD, Unsal-Kacmaz K, DeBerardinis RJ. Kim J, et al. Nat Metab. 2020 Dec;2(12):1401-1412. doi: 10.1038/s42255-020-00316-0. Epub 2020 Nov 30. Nat Metab. 2020. PMID: 33257855 Free PMC article.
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer.
Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, Torigian DA, Rodriguez D, Smith SA, Dean E, Domchek SM, Drapkin R, Shih IM, Brown EJ, Hwang WT, Armstrong DK, Gaillard S, Giuntoli R, Simpkins F. Wethington SL, et al. Clin Cancer Res. 2023 Aug 1;29(15):2800-2807. doi: 10.1158/1078-0432.CCR-22-2444. Clin Cancer Res. 2023. PMID: 37097611
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer.
Araujo HA, Pechuan-Jorge X, Zhou T, Do MT, Hu X, Rojas Alvarez FR, Salvatierra ME, Ibarguen HP, Lee R, Raghulan R, Shah H, Moreno Ayala MA, Chen K, Tovbis Shifrin N, Wu S, Solis Soto LM, Negrao MV, Gibbons DL, Hong DS, Roth JA, Heymach JV, Zhang J, Jiang J, Singh M, Smith JAM, Quintana E, Skoulidis F. Araujo HA, et al. Cancer Discov. 2024 Nov 1;14(11):2183-2208. doi: 10.1158/2159-8290.CD-24-0421. Cancer Discov. 2024. PMID: 38975897
Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling.
El Zarif T, Meador CB, Qiu X, Seo JH, Davidsohn MP, Savignano H, Lakshminarayanan G, McClure HM, Canniff J, Fortunato B, Li R, Banwait MK, Semaan K, Eid M, Long H, Hung YP, Mahadevan NR, Barbie DA, Oser MG, Piotrowska Z, Choueiri TK, Baca SC, Hata AN, Freedman ML, Berchuck JE. El Zarif T, et al. Clin Cancer Res. 2024 Sep 3;30(17):3798-3811. doi: 10.1158/1078-0432.CCR-24-0466. Clin Cancer Res. 2024. PMID: 38912901 Free PMC article.
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes.
Venkadakrishnan VB, Presser AG, Singh R, Booker MA, Traphagen NA, Weng K, Voss NCE, Mahadevan NR, Mizuno K, Puca L, Idahor O, Ku SY, Bakht MK, Borah AA, Herbert ZT, Tolstorukov MY, Barbie DA, Rickman DS, Brown M, Beltran H. Venkadakrishnan VB, et al. Nat Commun. 2024 Aug 8;15(1):6779. doi: 10.1038/s41467-024-51156-5. Nat Commun. 2024. PMID: 39117665 Free PMC article.
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Senapati J, et al. Clin Cancer Res. 2023 Nov 1;29(21):4352-4360. doi: 10.1158/1078-0432.CCR-23-1429. Clin Cancer Res. 2023. PMID: 37585491
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL.
Wenzl K, Stokes ME, Novak JP, Bock AM, Khan S, Hopper MA, Krull JE, Dropik AR, Walker JS, Sarangi V, Mwangi R, Ortiz M, Stong N, Huang CC, Maurer MJ, Rimsza L, Link BK, Slager SL, Asmann Y, Mondello P, Morin R, Ansell SM, Habermann TM, Witzig TE, Feldman AL, King RL, Nowakowski G, Cerhan JR, Gandhi AK, Novak AJ. Wenzl K, et al. Blood Cancer J. 2024 Jun 20;14(1):100. doi: 10.1038/s41408-024-01080-0. Blood Cancer J. 2024. PMID: 38902256 Free PMC article.
208 results